Genetic and nongenetic factors associated with warfarin doserequirements in Egyptian patients

Pharmacogenetics and Genomics

Volumn 21, Issue 3, 2011, Pages 130-135

  Shahin, Mohamed Hossam A ^a   Khalifa, Sherief I ^e   Gong, Yan ^f   Hammad, Lamiaa N ^b   Sallam, Mohamed T H ^c   El Shafey, Mostafa ^d   Ali, Shawky S ^d   Mohamed, Mohamed Eslam F ^f   Langaee, Taimour ^f   Johnson, Julie A ^f  

^a Departments of Pharmacy Practice and Clinical Pharmacy   (United States)

^b Egypt   (Egypt)

^c AIN SHAMS UNIVERSITY   (Egypt)

^d Al Azhar University   (Egypt)

^e QATAR UNIVERSITY   (Qatar)

^f UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

APOE; CALU; CYP2C9; CYP4F2; Egyptian; polymorphism; VKORC1; warfarin

Indexed keywords

APOLIPOPROTEIN E; DNA; WARFARIN;

ADULT; AFRICA; AGE DISTRIBUTION; ARTICLE; ASIAN; CONTROLLED STUDY; DEMOGRAPHY; DNA EXTRACTION; EGYPT; EUROPE; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEREDITY; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; POPULATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

EID: 79951682471     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283436b86     Document Type: Article

References (24)

1. Oldenburg J, Bevans CG, Fregin A, Geisen C, Muller-Reible C, Watzka M. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007; 98:570-578. (Pubitemid 47421551)
2. Gulseth MP, Grice GR, Dager WE. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Am J Health Syst Pharm 2009; 66:123-133.
3. Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, Kurnik D. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 2009; 113:3925-3930.
4. Scott SA, Edelmann L, Kornreich R, Desnick RJ. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 2008; 82:495-500.
5. Voora D, Koboldt DC, King CR, Lenzini PA, Eby CS, Porche-Sorbet R, et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87:445-451.
6. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006; 79:291-302.
7. Aquilante CL, Lobmeyer MT, Langaee TY, Johnson JA. Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy 2004; 24:720-726. (Pubitemid 38747856)
8. Cavallari LH, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87:459-464.
9. Perini JA, Struchiner CJ, Silva-Assuncao E, Suarez-Kurtz G. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin Pharmacol Ther 2010; 87:417-420.
10. Borgiani P, Ciccacci C, Forte V, Sirianni E, Novelli L, Bramanti P, et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 2009; 10:261-266.
11. Perez-Andreu V, Roldan V, Anton AI, Garcia-Barbera N, Corral J, Vicente V, et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 2009; 113:4977-4979.
12. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997; 7:405-409. (Pubitemid 27427552)
13. Van der Weide J, Steijns LS, Van Weelden MJ, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001; 11:287-291. (Pubitemid 32537401)
14. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73:1162-1169. (Pubitemid 37414228)
15. Ozcelik T, Kanaan M, Avraham KB, Yannoukakos D, Megarbane A, Tadmouri GO, et al. Collaborative genomics for human health and cooperation in the Mediterranean region. Nat Genet 2010; 42:641-645.
16. Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS-E, et al. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 2002; 53:596-603. (Pubitemid 34621785)
17. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111:4106-4112.
18. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009; 5:e1000433.
19. Kimmel SE, Christie J, Kealey C, Chen Z, Price M, Thorn CF, et al. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J 2008; 8:53-60.
20. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007; 121:23-34. (Pubitemid 46421137)
21. Lal S, Sandanaraj E, Jada SR, Kong MC, Lee LH, Goh BC, et al. Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients. Br J Clin Pharmacol 2008; 65:260-264. (Pubitemid 351171275)
22. Kohnke H, Scordo MG, Pengo V, Padrini R, Wadelius M. Apolipoprotein E (APOE) and warfarin dosing in an Italian population. Eur J Clin Pharmacol 2005; 61:781-783. (Pubitemid 41674266)
23. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360:753-764.
24. Schelleman H, Chen J, Chen Z, Christie J, Newcomb CW, Brensinger CM, et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther 2008; 84:332-339.